Monday, February 10, 2014 3:46:28 PM
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM